Product logins

Find logins to all Clarivate products below.


Diabetic Macular Edema | Treatment Algorithms | Claims Data Analysis | US | 2019

Diabetic macular edema (DME) is the accumulation of fluid in the macula due to leaking blood vessels resulting from diabetic retinopathy. Therapies targeting vascular endothelial growth factor (VEGF) have been shown to improve visual acuity in DME patients. The anti-VEGF agents used in the treatment of DME are Lucentis and Eylea—both approved for the treatment of DME—and off-label Avastin. In addition to the anti-VEGF therapies, two long-acting intravitreal corticosteroid implants, Ozurdex and Iluvien, were approved in the United States in 2014 for the treatment of DME. Given the competitive DME market, it is essential to understand how DME patients are currently being treated using real-world data.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed DME patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DME patients?
  • How have intravitreal corticosteroid implants been integrated into the treatment algorithm?
  • What proportion of DME patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of DME patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with DME?

CONTENT HIGHLIGHTS

Geographies

United States

Real World Data

Longitudinal patient-level claims data analysis

Key Drugs Covered

Avastin, Eylea, Iluvien, Lucentis, Ozurdex, triamcinolone

Key Analysis Provided

  • Brand/Therapy Usage Across Longitudinal Patient Sample
  • Newly Diagnosed Patient Analysis
  • Treatment Initiation and Progression Line of Therapy Analysis
  • Combination Therapy Analysis
  • Source of Business for Recently Treated Patients
  • Persistency and Compliance Analysis
  • Product-level Patient Flow Charts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…